Amgen Adopts A Two-Price Strategy For The U.S.’s First Marketed Humira-Referenced Biosimilar, Amjevita Read more
Inflation Reduction Act Favors Biologics Over Small Molecules: In The Long Term, This Could Partly Undermine Bill’s Effort To Contain Costs Read more
Cigna’s PBM Express Scripts Latest To Put Less Pricey Biosimilars Of Abbvie’s Humira On Preferred Drug List Read more
Inflation Reduction Act Provision Aims To Further Spur Biosimilar Uptake With Temporary Add-On Payment In Medicare Part B Read more